Cyxone receive ethical and regulatory approval from Hungary to start clinical Phase 2b study in RA
Cyxone (publ), a biotech company in autoimmune diseases, have received approval from the Hungarian Central Ethics Committee and the Medical Product Agency - National Institute of Pharmacy and Nutrition (OGYEI) to start a clinical Phase 2b study - APPRAIS - with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).APPRAIS is a multicenter, randomised, double-blinded, placebo-controlled clinical study where patients with moderate to severe RA, who have previously been treated with methotrexate with inadequate response, will be treated with
